{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-049406","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.142730+00:00","generated_at":"2026-05-21T06:34:47.240397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Applied DNA Q2 fiscal 2025 revenue up 6% to $983k; net loss narrows to $3.3M","bullets":["Total revenues $983k (+6% YoY); LineaRx up 44% while MDx testing fell 33%.","Net loss $3.3M vs $4.5M prior year; operating loss $3.5M; adjusted EBITDA -$3.3M.","Cash $6.8M at quarter end; expects quarterly cash burn to decline starting June 30, 2025.","GMP Site 1 validated; annual revenue capacity $10M-$30M; new customer orders for LineaDNA.","Submitted H5N1 diagnostic validation to NYSDOH; investor call on June 3, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-049406","json":"https://secwatch.observer/filing/0001104659-25-049406.json","markdown":"https://secwatch.observer/filing/0001104659-25-049406.md","text":"https://secwatch.observer/filing/0001104659-25-049406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465925049406/0001104659-25-049406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465925049406/tm2515261d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T06:34:47.240397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}